• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infect Dis Rep . Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary C

tetano

Editor, Senior Moderator
Infect Dis Rep


. 2022 Dec 26;15(1):24-33.
doi: 10.3390/idr15010003.
Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease


Tomoko Sugiura[SUP] 1 2 [/SUP], Hiroaki Sugiura[SUP] 2 [/SUP], Hiroaki Kato[SUP] 1 [/SUP], Yuko Nariai[SUP] 1 [/SUP], Yuuki Mizumoto[SUP] 1 [/SUP], Kozue Hanada[SUP] 2 [/SUP], Rieko Takahashi[SUP] 2 [/SUP], Yukari Hinotubo[SUP] 2 [/SUP], Naoko Tanaka[SUP] 2 [/SUP], Mutsumi Sasaki[SUP] 2 [/SUP], Haruki Eguchi[SUP] 3 [/SUP], Hiroki Kamino[SUP] 1 4 [/SUP], Takeshi Urano[SUP] 1 4 5 [/SUP]



Affiliations

Abstract

Despite the promising effectiveness of the coronavirus disease 2019 vaccination using an mRNA vaccine, the short efficacy duration and some poor responses to the vaccination remain major concerns. We aimed to clarify the monthly kinetics of the anti-SARS-CoV-2 spike receptor-binding domain antibody response after two doses of the BNT162b2 vaccine in a Japanese population. A chemiluminescent enzyme immunoassay (CLIA) and an enzyme-linked immunosorbent assay were used to measure the antibody levels in 81 Japanese adults (age, <65 years). The antibody levels increased 10-fold at 2-3 weeks following the second dose of BNT162b2 and declined thereafter to approximately 50%, 20%, and 10% of the peak levels at 2, 3, and 6 months, respectively. To compare the antibody titers among different groups, older adults (age, >65 years; n = 38) and patients with systemic lupus erythematosus (SLE, n = 14) were also investigated. A decline in the mean relative antibody titers was observed in older men compared with younger men and in patients with SLE compared with individuals aged <65 years. Although the antibody levels increased drastically following two BNT162b2 doses, they then declined rapidly. Furthermore, poor responders to the vaccination were observed. Repeated vaccinations are required to maintain high antibody levels.

Keywords: BNT162b2; COVID-19 vaccination; Japanese people; older men; systemic lupus erythematosus.
 
Back
Top Bottom